Barzolvolimab not checked

Celldex Therapeutics · CDX-0159

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
6 active
13 in total · 7 in the EU
Targets
—
None known yet

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
Tested for
Chronic Spontaneous Urticaria (3 trials), Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism, Prurigo Nodularis, Atopic Dermatitis
Main trialPhase 3
“The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.”In the company’s words, NCT06455202 on ClinicalTrials.gov
Other names
CDX-0159

Other drugs for Chronic Spontaneous Urticaria

All 23 drugs for Chronic Spontaneous Urticaria

Coming up2

Changes2

Last 90 days

Trials13

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 4 Aug 2026 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
Phase 3Active, not recruiting 12 Aug 2026 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Phase 3Recruiting Jun 2028 A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
Phase 3Enrolling by invitation Sep 2028 Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Phase 2Active, not recruiting 17 Mar 2026 A Study of Barzolvolimab in Patients With Prurigo Nodularis
Phase 2Active, not recruiting 6 May 2026 A Study of Barzolvolimab in Patients With Atopic Dermatitis
Phase 2Completed 28 Sep 2023 A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
Phase 2Completed 12 Jun 2024 A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
Phase 2Completed 4 Jun 2025 A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
Phase 1Completed 14 Jan 2022 A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
Phase 1Completed 16 Dec 2022 A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
Phase 1Completed 17 Jan 2023 A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
Phase 1Completed 31 Jul 2023 A Study of CDX-0159 in Patients With Prurigo Nodularis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Barzolvolimab

Following is part of Solo: you see every change to Barzolvolimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in